Publication Name	World Journal of Hepatology
Manuscript ID	13804
Country	France

Received	2014-09-02 09:38
Peer-Review Started	2014-09-02 20:53
To Make the First Decision	2014-11-27 12:12
Return for Revision	2014-12-04 16:40
Revised	2015-01-10 07:55
Second Decision	2015-02-04 11:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-02-11 16:24
Articles in Press	2015-02-11 16:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-20 14:33
Publish the Manuscript Online	2015-05-01 19:01

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy
Manuscript Source	Unsolicited Manuscript
All Author List	Chantal Dreyer, Marie-Paule Sablin, Mohamed Bouattour, Cindy Neuzillet, Maxime Ronot, Safi Dokmak, Jacques Belghiti, Nathalie Guedj, Valérie Paradis, Eric Raymond and Sandrine Faivre
Funding Agency and Grant Number	Funding Agency Grant Number Pfizer Inc, funding ACUMED (Tytherington, UK) for manuscript editing
Corresponding Author	Dr. Mohamed Bouattour, Department of Medical Oncology and Hepatology, Beaujon University Hospital (AP-HP - PRES Paris 7 Diderot), 100 boulevard du Général Leclerc, 92110 Clichy, France. mohamed.bouattour@bjn.aphp.fr
Key Words	Biliary tract tumors; Antiangiogenic therapy; Hypodensity; Tumor response; Vascular endothelial growth factor receptor inhibitors; Chemoresistance
Core Tip	No systemic therapy after progression on platinum-based chemotherapy is currently approved. Based on imaging hypervascular pattern and molecular expression of vascular endothelial growth factor, we evaluated sunitinib, a multikinase inhibitor as second line treatment in patients with advanced intrahepatic cholangiocarcinoma. We report 3 cases of disease control lasting 4-16 mo that provide the rational for developing prospective clinical trials with sunitinib in second line for advanced intrahepatic cholangiocarcinoma.
Publish Date	2015-05-01 19:01
Citation	Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol 2015; 7(6): 910-915
URL	http://www.wjgnet.com/1948-5182/full/v7/i6/910.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i6.910

Full Article (PDF)	WJH-7-910.pdf
Full Article (Word)	WJH-7-910.doc
Manuscript File	13804-Review.doc
Answering Reviewers	13804-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13804-Conflict-of-interest statement.pdf
Copyright License Agreement	13804-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	13804-Institutional review board statement.pdf
Peer-review Report	13804-Peer-review(s).pdf
Scientific Misconduct Check	13804-Scientific misconduct check.pdf
Scientific Editor Work List	13804-Scientific editor work list.pdf